- BIIB has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $1.1 billion.
- BIIB is up 2% today from today's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in BIIB with the Ticky from Trade-Ideas. See the FREE profile for BIIB NOW at Trade-Ideas More details on BIIB: Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. BIIB has a PE ratio of 27.9. Currently there are 12 analysts that rate Biogen a buy, no analysts rate it a sell, and 6 rate it a hold. The average volume for Biogen has been 2.0 million shares per day over the past 30 days. Biogen has a market cap of $90.8 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.62 and a short float of 1.3% with 0.89 days to cover. Shares are up 13.7% year-to-date as of the close of trading on Wednesday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.